Newsletter May 2024
EPO is advancing in vitro and in vivo glioblastoma portfolio
Dear Colleague,
We are pleased to share that our research activities in the GBM space are progressing steadily and we will be showcasing our work at the Brain Tumor Meeting at the Max Delbrück Center, Berlin, May 23 to 24.
At the meeting, EPO will report on its thoroughly characterized glioblastoma (GBM) PDX models and the establishment of a new panel of matching GBM PDX-derived glioma cell lines. These PDX-derived cell lines show individual cell morphologies and growth pattern, as well as expression of established cancer stem cell markers.
By establishing and continously expanding our in vitro/in vivo GBM pipeline, EPO is able to perform rapid in vitro sensitivity screenings in association with selection of suited models for subsequent in vivo studies as valuable tool for accelerated drug development. We are excited to continue leveraging our capabilites and scientific expertise in the GBM space to our clients, providing the best possible service to enhance your drug programs.
Please connect directly with our subject matter expert Turn on Javascript! to discuss your project. Additionally, we invite you to explore our comprehensive overview poster providing a detailed glimpse into our GBM expertise. (POSTER LINK)
Best wishes,
Jens Hoffmann & Wolfgang Walther
CEO & CSO at EPO Berlin-Buch